The use of propafenone in the treatment of atrial fibrillation

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Atrial fibrillation (AF) is the most common heart rhythm disorder requiring treatment, the prevalence of which increases with age. Pharmacological drugs are the first-line therapy for AF treatment. Antiarrhythmic drugs (AADs) are used as emergency therapy to terminate recently developed AF and to maintain sinus rhythm as a planned therapy to prevent recurrence of arrhythmia. The review presents data on the most commonly used AAD in clinical practice for the treatment of AF, propafenone. A distinctive feature of propafenone is the possibility of its use at all stages of medical care: outpatient, emergency, inpatient, both orally and intravenously. The drug can be used both to interrupt paroxysmal AF and to maintain sinus rhythm in planned therapy.

全文:

受限制的访问

作者简介

A. Syrov

Peoples’ Friendship University of Russia named after Patrice Lumumba

编辑信件的主要联系方式.
Email: syrman2002_1@yahoo.com
ORCID iD: 0000-0002-2536-5781

Cand. Sci. (Med.), Associate Professor

俄罗斯联邦, Moscow

参考

  1. Zulkifly H., Lip G., Lane D. Epidemiology of atrial fibrillation. Int J Clin Pract. 2018;72(3):13070. doi: 10.1111/ijcp.13070.
  2. Клинические рекомендации. Фибрилляция и трепетание предсердий у взрослых. Общероссийская общественная организация «Российское кардиологическое общество», Всероссийское научное общество специалистов по клинической электрофизиологии, аритмологии и электростимуляции, Ассоциация сердечно-сосудистых хирургов России. 2020. Рубрикатор клинических рекомендаций Минздрава России. ID: 382. URL: https://cr.minzdrav.gov.ru/schema/382_1 (дата обращения – 21.07.2024). [Clinical guidelines. Atrial fibrillation and flutter in adults. Russian Society of Cardiology, All-Russian Scientific Society of Specialists in Clinical Electrophysiology, Arrhythmology and Electrical Stimulation, Association of Cardiovascular Surgeons of Russia. 2020. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. ID: 382. URL: https://cr.minzdrav.gov.ru/schema/382_1 (date of access – 21.07.2024). (In Russ.)].
  3. European Society of Cardiology. 2020 guidelines for of atrial fibrillation. ESC clinical practice guidelines. URL: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Atrial-Fibrillation-Management (date of access – 21.07.2024).
  4. Benjamin E.J., Wolf P.A., D’Agostino R.B., et al. Impact of atrial fibrillation on the risk of death. The Framingham Study. Circulation 1998;98:946–52.
  5. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention. The AnTicoagulant and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–75.
  6. Anter E., Collans D.J., Wise D.G. Pharmacological and electrical conversion of atrial fibrillation sinus rhythm is worth to effort. Circulation 2009;120:1436–43.
  7. Haissaguerre M., Jais P., Shah D.C., et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659–66.
  8. Lu Z., Scherlag B.J., Lin J., et al. Atrial fibrillation begets atrial fibrillation. Autonomic mechanism for atrial electrical remodeling induced by short-term rapid atrial pacing. Circ Arrhythm Electrophysiol. 2008;1:184–92.
  9. Camm J. Antiarrhythmic drugs for the maintenance of sinus rhythm. Risks and benefits. Int J Cardiol. 2012;155(3):362–71. doi: 10.1016/j.ijcard.2011.06.012.
  10. Naccarelli G.V., Walbrette D.L., Khan M., et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation. Comparative efficacy and results of trials. Am J Cardiol. 2003;91(Sup- pl):15–26.
  11. Vaughan Williams E.M. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol. 1984;24(4): 129–47. doi: 10.1002/j.1552-4604.1984.tb01822.x.
  12. Valembois L., Audureau E., Takeda A. et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2019;9(9):CD005049. doi: 10.1002/14651858.CD005049.pub5.
  13. Lafuente-Lafuente C., Mouly S., Longas-Tejero M.A., Bergmann J.F. Antiarrhythmics for maintaining si- nus rhythm after cardioversion of atrial fibrillation. The Cochrane Library 2009;1:1–134.
  14. RxList. Propaphenone. URL: https://www.rxlist.com/consumer_propafenone_rythmol_rythmol_sr/drugs-condition.htm (date of access – 21.07.2024).
  15. Официальные инструкции по применению лекарственных препаратов с МНН пропафенон. Государственный реестр лекарственных средств Минздрава России. URL: https://grls.rosminzdrav.ru/ (дата обращения – 21.07.2024). [Official instructions for the use of medicinal products with the INN propafenone. State Register of Medicines of the Ministry of Health of Russia. URL: https://grls.rosminzdrav.ru/ (date of access – 21.07.2024). (In Russ.)].
  16. Giani P., Landolina M., Giudici V., et al. Pharmacokinetics and pharmacodynamics of propafenone during acute and chronic administration. Eur J Clin Pharmacol. 1988;34:187–94.
  17. Siddoway L.A., Roden D.M., Woosly R.L. Clinical pharmacology of propafenone. Pharmacokinetics, metabolism, and concentration-response relations. Am J Cardiol. 1984;54:9–12.
  18. Carlsson J., Miketic S., Windeler J. et al.; STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: The Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41(10):1690–96. doi: 10.1016/s0735-1097(03)00332-2.
  19. Hohnloser S., Kuck K., Lilienthal J. Rhythm or rate control in atrial fibrillation – Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial. Lancet. 2000;356(9244):1789–94. doi: 10.1016/s0140-6736(00)03230-x
  20. Karamichalakis N., Letsas K., Vlachos K., et al. Managing atrial fibrillation in the very elderly patient: Challenges and solutions. Vasc Health Risk Manag. 2015;11:555–62. doi: 10.2147/VHRM.S83664.
  21. Margheri M., Fradella G., Maioli M., et al. Efficacy of intravenous and per os propafenone in the ambulatory treatment of recent-onset atrial fibrillation. G Ital Cardiol. 1992;22(3):257–65.
  22. Boriani G., Capucci A., Lenzi T. et al. Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration. Chest. 1995;108(2):355–58. doi: 10.1378/chest.108.2.355
  23. Fresco C., Proclemer A., Pavan A. et al. Intravenous propafenone in paroxysmal atrial fibrillation: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Paroxysmal Atrial Fibrillation Italian Trial (PAFIT)-2 Investigators. Clin Cardiol. 1996;19(5):409–12. doi: 10.1002/clc.4960190515.
  24. Satullo G., Arrigo F., Cavallaro L., et al. A comparison between propafenone and hydroquinidine perorally in the treatment of recent-onset atrial fibrillation. Minerva Cardioangiol. 1996;44(3):141–44.
  25. Botto G., Capucci A., Bonini W., at al. Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: Comparison of two regimens. Int J Cardiol. 1997;58(1):55–61. doi: 10.1016/s0167-5273(96)02841-0.
  26. Boriani G., Biffi M., Capucci A., et al. Oral loading with propafenone: A placebo-controlled study in elderly and nonelderly patients with recent onset atrial fibrillation. Pacing Clin Electrophysiol. 1998;21(11Pt2):2465–69. doi: 10.1111/j.1540-8159.1998.tb01202.x.
  27. Antonelli D., Darawsha A., Rimbrot S., et al. Propafenone dose for emergency room conversion of paroxysmal atrial fibrillation. Harefuah. 1999;136(11):857–59.
  28. Blanc J., Voinov C., Maarek M. Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation. PARSIFAL Study Group. Am J Cardiol. 1999;84(9):1029–32. doi: 10.1016/s0002-9149(99)00493-2.
  29. Capucci A., Villiani G., Aschieri D. Safety of oral propafenone in the convertion of recept-onset atrial fibrillation to sinus rhythm: a prospective parallel placebo – controlled multicentred study. Int J Cardiol. 1999;68(2):187–96. doi: 10.1016/s0167-5273(98)00363-5.
  30. Madonia S., De Simone M., Brai G., et al. Intravenous versus oral initial load of propafenone for conversion of recent-onset atrial fibrillation in the emergency room: A randomized trial. Ital Heart J. 2000;1(7):475–79.
  31. Velazquez Rodriguez E., Cancino Rodriguez C., Arias Estrada S., et al. Pharmacological cardioversion with intravenous propafenone in atrial fibrillation. Arch Inst Cardiol Mex. 2000;70(2):160–66.
  32. Zadura M., Grossmann G., Modrzewska A. et al. [Comparison of efficacy, safety and cost-effectiveness of intravenous versus oral propafenone in paroxysmal atrial fibrillation. Pol Merkur Lekarski. 2001;11(62):137–39. (In Polish)].
  33. Alboni P., Botto G.L., Baldi N. et al. Outpation treatment of recent-onset atrial fibrillation with the «pill in pocket» approach. N Engl J Med. 2004;351(23):2384–91. doi: 10.1056/NEJMoa041233.
  34. Antonelli D., Freedberg N.A., Feldman A., at al. Intravenous propafenone for conversion of atrial fibrillation in the emergency room. Harefuah. 2004;143(7):471–74.
  35. Capucci A., Boriani G. Intravenous administration of propafenone. J Am Coll Cardiol. 1992;19(6):1368–69. doi: 10.1016/0735-1097(92)90350-v.
  36. Kochiadakis G.E., Igoumenidis N.E., Hamilos M.E., et al. A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation. Am J Cardiol. 2007;99(12):1721–25. doi: 10.1016/j.amjcard.2007.01.059.
  37. Kosior D.A., Kochanowski J., Scislo P., et al. Efficacy and tolerability of oral propafenone versus quinidine in the treatment of recent onset atrial fibrillation: A randomized, prospective study. Cardiol J. 2009;16(6):521–27.
  38. Balla I., Petrela E., Kondili A., et al. Pharmacological conversion of recent atrial fibrillation: A randomized, placebo-controlled study of three antiarrhythmic drugs. Anadolu Kardiyol Derg. 2011;11(7):600–6. doi: 10.5152/akd.2011.162.
  39. Лукьянова И.Ю., Кузнецов А.В., Комарницкий В.М., Козырева А.Г. Изучение эффективности и безопасности препаратов для медикаментозной кардиоверсии у больных с пароксизмальной формой фибрилляции предсердий на догоспитальном этапе. Скорая медицинская помощь. 2017;18(4):43–7. [Lukyanova I.Yu., Kuznetsov A.V., Komarnitsky V.M., Kozyreva A.G. Study of the effectiveness and safety of drugs for drug cardioversion in patients with paroxysmal atrial fibrillation at the prehospital stage. Emergency. 2017;18(4):43–7. (In Russ.)].
  40. Тарасов А.В., С.А.Косых С.А., Бушуева Е.В. и соавт. Сравнение эффективности инъекционных форм антиаритмических препаратов пропафенона и амиодарона при проведении фармакологической кардиоверсии пароксизмальной фибрилляции предсердий. Consilium Medicum. 2019;21(1):81–6. [Tarasov A.V., S.A. Kosykh S.A., Bushueva E.V. et al. Comparison of the effectiveness of injectable forms of antiarrhythmic drugs propafenone and amiodarone during pharmacological cardioversion of paroxysmal atrial fibrillation. Consilium Medicum. 2019;21(1):81–6. (In Russ.)].
  41. Antman E.M., Beamer A.D., Cantillon C., et al. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol. 1988;12(4):1005–11. doi: 10.1016/0735-1097(88)90468-8.
  42. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group. Circulation. 1995;92(9):2550–57.
  43. Bellandi F., Simonetti I., Leoncini M., et al. Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. Am J Cardiol. 2001;88(6): 640–45. doi: 10.1016/s0002-9149(01)01806-9.
  44. Lardoux H., Maison Blanche P., Marchand X., et al. Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study. Annales de Cardiologie et d Angeiologie 1996;45(8):469–79.
  45. Bellandi F., Dabizzi R.P., Niccoli L., et al. Propafenone and sotalol: long-term efficacy and tolerability in the prevention of paroxysmal atrial fibrillation. A placebo-controlled double-blind study. Giornale Italiano di Cardiologia. 1996;26(4):379–90.
  46. Bellandi F., Simonetti I., Leoncini M., et al. Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. Am J Cardiol. 2001;88(6):640–45.
  47. Chimienti M., Cullen M.T. Jr, Casadei G. Safety of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: Report from the Flecainide and Propafenone Italian Study Investigators. Am J Cardiol. 1996;77(3):60A–75A. doi: 10.1016/s0002-9149(97)89119-9.
  48. Meinertz T., Lip G., Lombardi F., et al. Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study). Am J Cardiol. 2002;90(12):1300–06.
  49. Pritchett E., Pagen R., Carlson M., et al; Rythmol Atrial Fibrillation Trial (RAFT) Investigators. Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. Am J Cardiol. 2003.15;92(8):941–46. doi: 10.1016/s0002-9149(03)00974-3.
  50. Kowey P.R., Yannicelli D., Amsterdam E.; COPPA-II Investigators. Effectiveness of oral propafenone for the prevention of atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 2004;94(5):663–65. doi: 10.1016/j.amjcard.2004.05.038.
  51. Фомина И.Г., Тарзиманова А.И., Вертлужский А.В. и др. Пропафенон при восстановлении синусового ритма у больных с персистирующей формой фибрилляции предсердий. «ПРОМЕТЕЙ» – открытое, мультицентровое, пилотное исследование в Российской Федерации. Кардиоваскулярная терапия и профилактика. 2005;4(4):66–9. [Fomina I.G., Tarzimanova A.I., Vertluzhsky A.V., et al. Propafenone in restoring sinus rhythm in patients with persistent atrial fibrillation. «PROMETHEUS» is an open, multicenter, pilot study in the Russian Federation. Cardiovascular therapy and prevention. 2005;4(4):66–9. (In Russ.)].
  52. Gulizia M., Mangiameli S., Orazi S., et al. A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: A Group for Observation and Research on Atrial Arrhythmias (PITAGORA) trial. Am Heart J. 2008;155(1):100–7,107.e1. doi: 10.1016/ j.ahj.2007.08.033.
  53. Оганов Р.Г., Симаненков В.И., Бакулин И.Г. и др. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019;18(1):5–66. [Oganov R.G., Simanenkov V.I., Bakulin I.G. et al. Comorbid pathology in clinical practice. Algorithms for diagnosis and treatment. Cardiovascular therapy and prevention. 2019;18(1):5–66. (In Russ.)].

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2024